Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

55.03 -0.41 (-0.73%)

Delayed Quote Updated: 10:55 AM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

37 38 Next >

Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen. ↗

February 09, 2023

CRISPR shares are ripe for a rebound after dropping 46% last year.

Via The Motley Fool

1 Beaten-Down Stock That Has a Lot to Prove in 2023 ↗

February 08, 2023

This biotech looks like a high-risk, high-reward play.

Via The Motley Fool

3 Top Stocks to Buy If There Is a Market Pullback ↗

February 07, 2023

All three of these stocks performed well as the market fell in 2022.

Via The Motley Fool

Ready to Buy the Dip? Consider This Gene Editing Stock ↗

February 06, 2023

CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back.

Via The Motley Fool

3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129% ↗

February 06, 2023

Cathie Wood is bullish about these stocks. And so are Wall Street analysts.

Via The Motley Fool

When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗

February 05, 2023

A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Via Talk Markets

5 Reasons to Buy Vertex Pharmaceuticals Now ↗

January 18, 2023

Vertex shares are extending last year's gains, and that trend probably isn't over.

Via The Motley Fool

Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗

January 14, 2023

Vertex is heading for a new phase of growth.

Via The Motley Fool

3 No-Brainer Growth Stocks to Buy in 2023 ↗

February 03, 2023

These stocks all fell by double digits last year.

Via The Motley Fool

Why Editas Medicine's Shares Jumped This Week ↗

February 03, 2023

The gene-editing biotech's shares have had a strong two-week run.

Via The Motley Fool

Is Editas Medicine Stock a Buy Now? ↗

February 03, 2023

Layoffs and a thin clinical-stage pipeline aren't very encouraging.

Via The Motley Fool

3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later ↗

February 02, 2023

CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.

Via InvestorPlace

Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now? ↗

February 02, 2023

Michael Burry thinks investors should sell stocks right now. Jim Cramer thinks they should buy more. Which expert is right in this case?

Via InvestorPlace

Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock ↗

February 01, 2023

Via Benzinga

Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly' ↗

February 01, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc (NASDAQ: XM) as a

Via Benzinga

3 Things About CRISPR Therapeutics That Smart Investors Know ↗

January 31, 2023

The gene-therapy specialist's near-term outlook is quite bullish.

Via The Motley Fool

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

3 Healthcare Stocks to Buy and Hold for the Next 10 Years ↗

January 27, 2023

These companies have the therapies to boost revenue for a decade.

Via The Motley Fool

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later ↗

January 25, 2023

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

Via InvestorPlace

3 Gene Editing Stocks With the Best Long-Term Potential ↗

January 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Via InvestorPlace

Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics? ↗

January 22, 2023

Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.

Via The Motley Fool

3 Smart Stocks to Buy if a Recession Is on the Way ↗

January 21, 2023

Their products will enjoy strong demand regardless of what happens with the economy.

Via The Motley Fool

CRISPR Therapeutics Stock: Bull vs. Bear ↗

January 19, 2023

Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market?

Via The Motley Fool

7 Biotech Stocks That Will Make You Rich in 10 Years ↗

January 18, 2023

Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.

Via InvestorPlace

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years ↗

January 18, 2023

CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years.

Via InvestorPlace

2 Stocks Down More Than 25% to Buy Right Now ↗

January 16, 2023

These companies are set for a new era of growth.

Via The Motley Fool

5 Potentially Explosive Stocks to Buy in 2023 ↗

January 13, 2023

These stocks all dropped in the double digits last year. But their future prospects are brilliant.

Via The Motley Fool

More Likely to 5X First: CRISPR Therapeutics vs. InMode ↗

January 12, 2023

These two companies are in very different situations but could generate significant returns for investors.

Via The Motley Fool

2 Growth Stocks You May Regret not Buying Right Now ↗

January 11, 2023

At their beaten-down valuations, these stocks have the potential to deliver some impressive returns.

Via The Motley Fool

Can Cathie Wood Bounce Back in 2023? ↗

January 11, 2023

Wood sticks by her strategy, no matter what the general market does.

Via The Motley Fool

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

37 38 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.